Traitement Obésité Perte de poids Médicaments Lorcaserin HCl

Traitement Obésité Perte de poids Médicaments Lorcaserin HCl

Détail rapide

Product name Lorcaserin, Lorcaserin HCL
Synonyms Belviq ; (R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benz ; Lorcaserin Hydrochloride
CAS numbers: 616202-92-7
Formule moléculaire : C11H14ClN
Masse moléculaire : 195.6886
Essai : 99%
Point d'ébullition : 288.125°C at 760 mmHg
Point d'éclair : 128.054°C
Apparence : poudre blanche
Product usage : Medicine reducing weight and antidepressants

Description du produit

Lorcaserin HCl is a FDA-approved prescription weight loss drug that, when used in conjunction with diet and exercise, can help some weight-related medical problems overweight adults or obese adults lose weight and maintain physical condition. It is not known whether lovastatin HCl is safe and effective with other prescription, non-prescription or herbal weight loss products.

It is not known whether chlorotastatin HCl will change the risk of heart problems, stroke or death due to heart disease or stroke. Lomizine Hydrochloride is a serotonin 2C receptor agonist. By selectively activating the serotonin 2C receptor in the brain, it has been shown to reduce food consumption and promote SA anxiety. Carbacillin specifically expresses a cofactor for reducing calorie diets and increases physical activity (BMI of 30 kg / m2 or greater) and overweight adults (BMI of 27 kg / m2) for chronic weight management in clinically obese patients ), Which has at least one weight-related comorbid condition. As a tablet designed for oral administration. The recommended dose is 10mg tablets twice daily. If the treatment did not reach 5% of the weight loss at week 12, HCl should be discontinued using chlorhexidine.

Lorcaserin HCl Applications:

Belviq(Lorcaserin hydrochloride) is a serotonin 2C receptor agonist. It has been shown that by selectively activating the serotonin 2C receptor in the brain to reduce food consumption and promote satiety.

Belviq(Lorcaserin hydrochloride) is specifically indicated as an adjunct to a reduced-calorie diet andincreased physical activity for chronic weight management in clinically obeseadults (BMI of 30 kg/m2 or greater) and overweight adults (BMI of 27 kg/m2 orgreater) with at least one weight-related comorbid condition.